Home > Insider Trading > Filing (0001365618-10-000007)

Filing Details

Accession Number:: 0001365618-10-000007
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-12-02 12:00:00
Reporting Period:: 2010-11-30

Filing Date:: 2010-12-02
Accepted Time:: 2010-12-02 15:09:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1411158	Anacor Pharmaceuticals Inc	ANAC	Pharmaceutical Preparations (2834)	251854385

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1365618	D Anders Hove	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-11-30	1,752,808	$0.00	1,752,808	No	4	C	Indirect	By Funds
Common Stock	Acquisiton	2010-11-30	133,622	$0.00	1,886,430	No	4	C	Indirect	By Funds
Common Stock	Acquisiton	2010-11-30	139,105	$0.00	2,025,535	No	4	C	Indirect	By Funds
Common Stock	Acquisiton	2010-11-30	600,000	$5.00	2,625,535	No	4	P	Indirect	By Funds
Common Stock	Acquisiton	2010-11-30	2,000,000	$5.00	4,625,535	No	4	A	Indirect	By Funds

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Funds
No	4	C	Indirect	By Funds
No	4	C	Indirect	By Funds
No	4	P	Indirect	By Funds
No	4	A	Indirect	By Funds

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Convertible Preferred Stock	Disposition	2010-11-30	1,752,808	$0.00	1,752,808	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2010-11-30	133,622	$0.00	133,622	$0.00
Common Stock	Series E Convertible Preferred Stock	Disposition	2010-11-30	139,105	$0.00	139,105	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of the Issuer's Series C Convertible Preferred Stock, Series D Convertible Preferred Stock and Series E Convertible Preferred Stock automatically converted into shares of common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering.
The Issuer's Series C Convertible Preferred Stock, Series D Convertible Preferred Stock and Series E Convertible Preferred Stock do not have an expiration date and automatically converted into shares of common stock upon the closing of the Issuer's initial public offering.
The shares, on a post conversion basis, are held as follows: 1,426,786 shares held by Venrock Associates IV, L.P. ("VAIV"), 290,966 shares held by Venrock Partners, L.P. ("VP") and 35,056 shares held by Venrock Entrepreneurs Fund IV, L.P. ("VEFIV"). Venrock Management IV, LLC, Venrock Partners Management, LLC and VEF Management IV, LLC (together, the "Venrock GP Entities") are the sole general partners of VAIV, VP and VEFIV, respectively (together, the "Venrock Funds"), and have voting and investment power over the shares held by the Venrock Funds. Anders D. Hove is a Member of each of the Venrock GP Entities, and Dr. Hove disclaims beneficial ownership of the shares held by the Venrock Funds, except to the extent of his indirect pecuniary interest therein.
The shares, on a post conversion basis, are held as follows: 108,769 shares held by VAIV, 22,181 shares held by VP and 2,672 shares held by VEFIV. Venrock Management IV, LLC, Venrock Partners Management, LLC and VEF Management IV, LLC are the sole general partners of VAIV, VP and VEFIV, respectively, and have voting and investment power over the shares held by the Venrock Funds. Anders D. Hove is a Member of each of the Venrock GP Entities, and Dr. Hove disclaims beneficial ownership of the shares held by the Venrock Funds, except to the extent of his indirect pecuniary interest therein.
The shares, on a post conversion basis, are held as follows: 113,232 shares held by VAIV, 23,091 shares held by VP and 2,782 shares held by VEFIV. Venrock Management IV, LLC, Venrock Partners Management, LLC and VEF Management IV, LLC are the sole general partners of VAIV, VP and VEFIV, respectively, and have voting and investment power over the shares held by the Venrock Funds. Anders D. Hove is a Member of each of the Venrock GP Entities, and Dr. Hove disclaims beneficial ownership of the shares held by the Venrock Funds, except to the extent of his indirect pecuniary interest therein.
The shares are held as follows: 1,426,786 shares held by VAIV, 290,966 shares held by VP and 35,056 shares held by VEFIV. Venrock Management IV, LLC, Venrock Partners Management, LLC and VEF Management IV, LLC are the sole general partners of VAIV, VP and VEFIV, respectively, and have voting and investment power over the shares held by the Venrock Funds. Anders D. Hove is a Member of each of the Venrock GP Entities, and Dr. Hove disclaims beneficial ownership of the shares held by the Venrock Funds, except to the extent of his indirect pecuniary interest therein.
The shares are held as follows: 1,535,555 shares held by VAIV, 313,147 shares held by VP and 37,728 shares held by VEFIV. Venrock Management IV, LLC, Venrock Partners Management, LLC and VEF Management IV, LLC are the sole general partners of VAIV, VP and VEFIV, respectively, and have voting and investment power over the shares held by the Venrock Funds. Anders D. Hove is a Member of each of the Venrock GP Entities, and Dr. Hove disclaims beneficial ownership of the shares held by the Venrock Funds, except to the extent of his indirect pecuniary interest therein.
The shares are held as follows: 1,648,787 shares held by VAIV, 336,238 shares held by VP and 40,510 shares held by VEFIV. Venrock Management IV, LLC, Venrock Partners Management, LLC and VEF Management IV, LLC are the sole general partners of VAIV, VP and VEFIV, respectively, and have voting and investment power over the shares held by the Venrock Funds. Anders D. Hove is a Member of each of the Venrock GP Entities, and Dr. Hove disclaims beneficial ownership of the shares held by the Venrock Funds, except to the extent of his indirect pecuniary interest therein.
The shares are held as follows: 2,137,187 shares held by VAIV, 435,838 shares held by VP and 52,510 shares held by VEFIV. Venrock Management IV, LLC, Venrock Partners Management, LLC and VEF Management IV, LLC are the sole general partners of VAIV, VP and VEFIV, respectively, and have voting and investment power over the shares held by the Venrock Funds. Anders D. Hove is a Member of each of the Venrock GP Entities, and Dr. Hove disclaims beneficial ownership of the shares held by the Venrock Funds, except to the extent of his indirect pecuniary interest therein.
1,690,722 shares of common stock are held directly by Venrock Healthcare Capital Partners, L.P. ("VHCP"). VHCP Management, LLC ("VHCP Management") is the general partner of VHCP and may be deemed to beneficially own these shares. Messrs. Hove and Bryan Roberts are the managing members of VHCP Management and may be deemed to beneficially own these shares. Dr. Hove disclaims beneficial ownership of these shares, except to the extent of his indirect pecuniary interest therein.
309,278 shares of common stock are held directly by Venrock Co-Investment Holdings, LLC ("Venrock Co-Investment"). VHCP Management is the manager of Venrock Co-Investment and may be deemed to beneficially own these shares. Messrs. Hove and Roberts are the managing members of VHCP Management and may be deemed to beneficially own these shares. Dr. Hove disclaims beneficial ownership of these shares, except to the extent of his indirect pecuniary interest therein.